酒精性肝病患者酒精应用障碍管理

doi:10.3969/j.issn.1672-5069.2025.01.001

摘要/Abstract

Key words: Alcoholic liver disease, Alcohol consumption disorder, Treatment, Progress

孙福荣, 王炳元. 酒精性肝病患者酒精应用障碍管理[J]. 实用肝脏病杂志, 2025, 28(1): 1-4.

Sun Furong, Wang Bingyuan. Management of patients with alcohol consumption disorder[J]. Journal of Practical Hepatology, 2025, 28(1): 1-4.

[1] Schomerus G, Leonhard A, Manthey J,et al. The stigma of alcohol-related liver disease and its impact on healthcare. J Hepatol, 2022,77(2):516-524.
[2] Banini BA, Sanyal AJ. Treatment of NASH: What helps beyond weight loss? Am J Gastroenterol, 2017,112(6):821-824.
[3] Zhang X, Zhang X, Liu M, et al. Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. BMC Gastroenterol, 2022,22(1):484.
[4] Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: Liver. Am J Transplant, 2017,17(Suppl 1):174-251.
[5] Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-associated liver disease. Am J Gastroenterol, 2024, 119(1):30-54.
[6] Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol, 2019,17(11):2320-2329.
[7] Younossi ZM, Stepanova M, Ong J, et al. Global NASH Council. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol, 2019,17(8):1625-1633.
[8] Rinella ME, Lazarus JV, Ratziu V, et al. NAFLD nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol, 2024,29(1):101133.
[9] Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol, 2013,177(4):333-342.
[10] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023,77(5):1797-1835.
[11] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023,77(5):1797-1835.
[12] Ndugga N, Lightbourne TG, Javaherian K, et al. Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open, 2017,7(3):e013620.
[13] Shoreibah M, Anand BS, Singal AK. Alcoholic hepatitis and concomitant hepatitis C virus infection. World J Gastroenterol, 2014,20(34):11929-11934.
[14] Singal AK, Leggio L, DiMartini A. Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin. Liver Transpl, 2024,30(2):200-212.
[15] Monnig MA, Treloar Padovano H, Monti PM. Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities. Front Public Health, 2024,12:1322460.
[16] Louvet A, Labreuche J, Artru F, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology, 2017,66(5):1464-1473.
[17] Pearson MM, Kim NJ, Berry K, et al. Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis. Hepatol Commun, 2021,5(12):2080-2095.
[18] Mellinger JL, Scott Winder G, DeJonckheere M, et al. Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. J Subst Abuse Treat, 2018,91:20-27.
[19] Haque LY, Zuluaga P, Muga R, et al. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. Addict Sci Clin Pract, 2024,19(1):19.
[20] Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2020,71(1):306-333.
[21] Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med, 2018,379(13):1251-1261.
[22] Vannier AGL, Shay JES, Fomin V, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open, 2022,5(5):e2213014.
[23] Vannier AGL, Przybyszewski EM, Shay J, et al. Psychotherapy for alcohol use disorder is associated with reduced fisk of incident alcohol-associated liver disease. Clin Gastroenterol Hepatol, 2023,21(6):1571-1580,e7.
[24] Shah ND, Ventura-Cots M, Abraldes JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol, 2019,17(11):2320-2329,e12.
[25] He Y, Hwang S, Ahmed YA, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol, 2021,18(1):18-37.
[26] Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol, 2019,70(2):273-283.
[27] Nilsson E, Anderson H, Sargenti K, et al. Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther, 2019 ,49(11):1421-1430.

酒精性肝病患者酒精应用障碍管理

Management of patients with alcohol consumption disorder

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏雅, 王炳元. 酒精性肝病不是代谢相关性脂肪性肝病[J]. 实用肝脏病杂志, 2025, 28(1): 5-8.
[2]	赵彩霞, 杨松. 粪菌移植治疗重症酒精性肝炎研究进展^*[J]. 实用肝脏病杂志, 2025, 28(1): 9-12.
[3]	颜家佳, 杨蕊旭, 范建高. 美国胃肠病学学院酒精性肝病临床实践指南简介与解读[J]. 实用肝脏病杂志, 2025, 28(1): 17-19.
[4]	王菲, 刘迎宾, 赵媛媛. 聚乙二醇干扰素α-2a联合艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 40-43.
[5]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[6]	郭珍, 王欣, 牛攀霞. 血清HBsAg阳性的肺结核患者抗痨治疗引起病毒再激活和药物性肝损伤发生影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 68-71.
[7]	沈莉莉, 赵琳, 石磊. 失代偿期乙型肝炎肝硬化并发自发性细菌性腹膜炎患者第三代头孢菌素类耐药情况调查^*[J]. 实用肝脏病杂志, 2025, 28(1): 88-91.
[8]	朱瑞农, 宋丽群, 钱佶. 生长抑素联合内镜下治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 104-107.
[9]	卓宇宏, 陈平湖, 陈鸿程, 周思君, 陈小云, 范微微, 叶石才. 内镜下套扎术联合生长抑素治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 108-111.
[10]	王文栋, 梁茂全, 刘玉岩. 经颈静脉肝内门体分流术联合部分脾动脉栓塞术治疗肝硬化并发门脉高压症患者门静脉血流动力学变化研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 120-123.
[11]	杨爽, 高学松, 段雪飞. 难治性原发性胆汁性胆管炎研究进展^*[J]. 实用肝脏病杂志, 2025, 28(1): 156-159.
[12]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[13]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[14]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.
[15]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.